- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05321927
TENS in Persons With MS
Transcutaneous Electrical Nerve Stimulation in Persons With MS
Persons with multiple sclerosis (pwMS) often have an increased sense of fatigue. Furthermore, they present walking difficulties which negatively affects their mobility and results in an additional increase of fatigue. Previous literature suggests that transcutaneous electrical nerve stimulation (TENS) of leg muscles might increase their walking capacity and decrease perception of fatigue. In the present study we aim to investigate whether TENS of leg muscles reduces walking difficulties and sense of fatigue in pwMS in comparison with a short strength training protocol or no training. A similar aim is addressed after TENS of elbow flexor muscles.
Subjects with relapsing remitting or progressive MS, will undergo transcutaneous electrical nerve stimulation (TENS), strength exercises (SExerc), both TENS and SExerc (COMB) simultaneously, or sham stimulation without training (CON) of both leg and arm muscles. Force and fatigue measurements are performed before, directly after and three weeks after the training sessions and contain walking, fatigue, and strength assessments.
Main study parameters are changes in the scores of i) the six-minute walking test (6-MWT), ii) the perceived walking disability (MSWS-12) and iii) fatigue questionnaires (FSS and MFIS). Additional study parameters are changes in muscle force and muscle fatigability.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Groningen, Netherlands, 9713 AW
- University Medical Centre Groningen
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- EDSS score < 7
- MSWS score > 30
- FSS score > 4 or MFIS score > 38.
- no known cardiovascular disorder or having a positive advice on a sport medical examination
Exclusion Criteria:
- being a participant in an exercise study
- having a psychiatric disorder
- having cognitive or communication problems which reduces the capacity to understand instructions
- planned a change in medication during the training period
- having a neurological disorder other than MS
- having cardiovascular disorders and no positive advice from a sport medical examination
- having a pacemaker or another implantable electronic apparatus.
- being pregnant
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Sham Comparator: Control group
Sham stimulation will be applied over quadriceps femoris and biceps brachii on both sides for 10 min to each muscle group, one at a time.
Stimulation is delivered for 10 min to each muscle group, in three 10 minute sessions per week, for 4 weeks.
|
Continuous stimulation at 1 Hz for 2 seconds, then no stimulation for 10 seconds.
This will alternate for 10 minutes.
The intensity equals the intensity that is just felt by the individual.
|
|
Active Comparator: Strength-training group
Three training sessions for 10 minutes per muscle group per week, for 4 weeks during which sham stimulation will be applied.
|
Continuous stimulation at 1 Hz for 2 seconds, then no stimulation for 10 seconds.
This will alternate for 10 minutes.
The intensity equals the intensity that is just felt by the individual.
Three training sessions for 10 minutes per muscle, per week, for four weeks in total.
|
|
Active Comparator: Trancutaneous Electrical Nerve Stimulation (TENS)
Trancutaneous Electrical Nerve Stimulation (TENS) stimulation applied quadriceps femoris and biceps brachii on both sides for 10 min to each muscle group, one at a time.
Stimulation is delivered for 10 min to each muscle group, in three 10 minute sessions per week, for 4 weeks.
|
Transcutaneous Electrical Nerve Stimulation produces an electrical current to stimulate the nerves for therapeutic purposes.
continuous high frequency (≥ 50 Hz) stimulation for 5 minutes followed by high frequency (≥ 50 Hz) bursts with 7 pulses per burst for the last 5 minutes.
Other Names:
|
|
Experimental: TENS with strength training
Three training sessions for 10 minutes per target muscle group per week, for 4 weeks during which Trancutaneous Electrical Nerve Stimulation (TENS) stimulation is applied quadriceps femoris and biceps brachii on both sides.
|
Three training sessions for 10 minutes per muscle, per week, for four weeks in total.
Transcutaneous Electrical Nerve Stimulation produces an electrical current to stimulate the nerves for therapeutic purposes.
continuous high frequency (≥ 50 Hz) stimulation for 5 minutes followed by high frequency (≥ 50 Hz) bursts with 7 pulses per burst for the last 5 minutes.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
6-minute walk test
Time Frame: 6 weeks
|
This test assesses submaximal aerobic capactity.
Subjects walk for 6 minutes starting at mark on the floor at the beginning of a 30-m long hallway and walk to the next mark at the end of the hallway as quickly as possible, but safely.
The distance which is walked by the subject is measured.
Subjects may use assistive devices when performing the task.
|
6 weeks
|
|
chair-stand test
Time Frame: 6 weeks
|
This test assesses functional lower extremity strength.
Subjects sit on a chair and stand up repeatedly for 30 s. Arms of the subject are crossed and held against the chest.
The number of cycles of standing up from sitting are counted.
|
6 weeks
|
|
Fatigue Severity Scale (FSS)
Time Frame: 6 weeks
|
This is a questionnaire related to the impact of fatigue on daily life.
The questionnaire consists of 9 questions with a 7-point scale ranging from 'completely agree' to 'completely disagree'.
The total score ranges from 9 to 63; higher scores reflect a higher impact.
|
6 weeks
|
|
Modified Fatigue Impact Scale (MFIS)
Time Frame: 6 weeks
|
This is a questionnaire related to sense of fatigue.
The questionnaire consist of 21 questions providing assessment of the effect of fatigue in terms of physical, cognitive and psychosocial function.
The total score ranges from 0 to 84; higher scores reflect a higher impact of fatigue.
|
6 weeks
|
|
12-item MS walking scale (MSWS-12)
Time Frame: 6 weeks
|
This is a patient-base measure of walking ability.
The questionnaire consists of 12 items with a 5-point scale ranging from 'not at all' to 'extremely'.
The total score ranges from 5 to 60, with higher scores reflecting more walking difficulties.
|
6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Elbow flexor muscle force (maximal and submaximal levels)
Time Frame: 6 weeks
|
Maximal voluntary force (MVC) of the elbow flexors is measured with a custom-built dynamometer.
Subjects are seated in a chair with their arm abducted and in 90° of flexion with their non-dominant arm strapped to the force transducer.
Subjects are instructed to contract their elbow flexors as rapidly and forcefully as possible and to maintain force generation for 5 s.
MVC is determined as the peak force.
|
6 weeks
|
|
Knee extensor muscle force (maximal and submaximal levels)
Time Frame: 6 weeks
|
Maximal voluntary force (MVC) of the knee extensors is measured with a custom-built dynamometer.
Subjects are seated in a chair with the knee and hip in 90° of flexion with their non-dominant lower leg strapped to the chair's lever arm (~ 10 cm up to lateral malleolus).
Subjects are instructed to contract their knee extensors as rapidly and forcefully as possible and to maintain force generation for 5 s.
MVC is determined as the peak force.
|
6 weeks
|
|
Handgrip force
Time Frame: 6 weeks
|
Maximal voluntary force (MVC) of the handgrip is measured with a hydraulic hand dynamometer (JAMAR Hand Dynamometer).
The measurement is repeated 3 times and averaged.
|
6 weeks
|
|
Effort during submaximal contractions with elbow flexors
Time Frame: 6 weeks
|
Subjects are asked to produce different submaximal force levels of the elbow flexors (20, 30, 50 and 70%) and rate their perceived effort (scale 1-10) that was needed to generate this force level.
|
6 weeks
|
|
Effort during submaximal contractions with knee extensors
Time Frame: 6 weeks
|
Subjects are asked to produce different submaximal force levels of the knee extensors (20, 30, 50 and 70%) and rate their perceived effort (scale 1-10) that was needed to generate this force level.
|
6 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Multiple Sclerosis Quality of Life-54 (MSQOL-54)
Time Frame: 6 weeks
|
A self-report questionnaire with 54 items used to quantify health-related quality of life.
Generates two separate composite scores for physical and mental health (0-100); higher scores indicate better quality of life.
|
6 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Inge CAT Zijdewind, PhD, UMCG
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MS-STIM
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
Cabaletta BioNot yet recruitingProgressive Multiple Sclerosis | Multiple Sclerosis | Multiple Sclerosis (Relapsing Remitting) | Relapsing Multiple Sclerosis (RMS) | Progressive Multiple Sclerosis (PMS) | Multiple Sclerosis (MS) - Relapsing-remitting | Multiple Sclerosis - Relapsing Remitting
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsActive, not recruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
Novartis PharmaceuticalsCompletedRelapsing-remitting Multiple Sclerosis | Active Secondary Progressive Multiple SclerosisJapan
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
Clinical Trials on Sham stimulation
-
National Cheng-Kung University HospitalRecruiting
-
Washington University School of MedicineCompleted
-
Sheba Medical CenterSuspended
-
Georgia Institute of TechnologyEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompleted
-
Beijing Tiantan HospitalPeking Union Medical College Hospital; China-Japan Friendship Hospital; The First...Unknown
-
Tianjin Anding HospitalChinese Academy of SciencesEnrolling by invitationSchizophrenia Negative TypeChina
-
Dr. med. Carlo CeredaUniversity Hospital Inselspital, Berne; CLINICA HILDEBRAND CENTRO DI RIABILITAZIONE... and other collaboratorsUnknownIschemic Stroke | First Ever Clinical Stroke | Subacute Phase | Persistent Hemiparesis of Upper ExtremitySwitzerland
-
VA Office of Research and DevelopmentNot yet recruitingAttention Deficit Disorder With HyperactivityUnited States
-
University of PittsburghCompleted
-
Christian BaumannETH ZurichRecruitingParkinson Disease | Mild Cognitive Impairment | Huntington DiseaseSwitzerland